Adam S Barnett1, Sunghee Kim1, Gregg C Fonarow1, Laine E Thomas1, James A Reiffel1, Larry A Allen1, James V Freeman1, Gerald Naccarelli1, Kenneth W Mahaffey1, Alan S Go1, Peter R Kowey1, Jack E Ansell1, Bernard J Gersh1, Elaine M Hylek1, Eric D Peterson1, Jonathan P Piccini2. 1. From the Duke Center for Atrial Fibrillation, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.S.B., S.K., L.E.T., E.D.P., J.P.P.); Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center (G.C.F.); Columbia University College of Physicians and Surgeons, New York, NY (J.A.R.); University of Colorado School of Medicine, Aurora (L.A.A.); Yale University School of Medicine, New Haven, CT (J.V.F.); Penn State Hershey Heart and Vascular Institute (G.N.); Stanford University School of Medicine, CA (K.W.M.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); Lankenau Institute for Medical Research and Jefferson Medical College, Philadelphia, PA (P.R.K.); Hofstra Northwell School of Medicine, New York, NY (J.E.A.); Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN (B.J.G.); and Boston University Medical Center, MA (E.M.H.). 2. From the Duke Center for Atrial Fibrillation, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.S.B., S.K., L.E.T., E.D.P., J.P.P.); Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center (G.C.F.); Columbia University College of Physicians and Surgeons, New York, NY (J.A.R.); University of Colorado School of Medicine, Aurora (L.A.A.); Yale University School of Medicine, New Haven, CT (J.V.F.); Penn State Hershey Heart and Vascular Institute (G.N.); Stanford University School of Medicine, CA (K.W.M.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); Lankenau Institute for Medical Research and Jefferson Medical College, Philadelphia, PA (P.R.K.); Hofstra Northwell School of Medicine, New York, NY (J.E.A.); Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN (B.J.G.); and Boston University Medical Center, MA (E.M.H.). jonathan.piccini@duke.edu adam.barnett@duke.edu.
Abstract
BACKGROUND: It is unclear how frequently patients with atrial fibrillation receive guideline-concordant (GC) care and whether guideline concordance is associated with improved outcomes. METHODS AND RESULTS: Using data from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we determined how frequently patients received care that was concordant with 11 recommendations from the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society atrial fibrillation guidelines pertaining to antithrombotic therapy, rate control, and antiarrhythmic medications. We also analyzed the association between GC care and clinical outcomes at both the patient level and center level. A total of 9570 patients were included. The median age was 75 years (interquartile range, 67-82), and the median CHA2DS2-VASc score was 4 (interquartile range, 3-5). A total of 5977 patients (62.5%) received care that was concordant with all guideline recommendations for which they were eligible. Rates of GC care were higher in patients treated by providers with greater specialization in arrhythmias (60.0%, 62.4%, and 67.0% for primary care physicians, cardiologists, and electrophysiologists, respectively; P<0.001). During a median of 30 months of follow-up, patients treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization. CONCLUSIONS: Over a third of patients with atrial fibrillation in this large outpatient registry received care that differed in some respect from guideline recommendations. There was no apparent association between GC care and improved risk-adjusted outcomes.
BACKGROUND: It is unclear how frequently patients with atrial fibrillation receive guideline-concordant (GC) care and whether guideline concordance is associated with improved outcomes. METHODS AND RESULTS: Using data from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we determined how frequently patients received care that was concordant with 11 recommendations from the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society atrial fibrillation guidelines pertaining to antithrombotic therapy, rate control, and antiarrhythmic medications. We also analyzed the association between GC care and clinical outcomes at both the patient level and center level. A total of 9570 patients were included. The median age was 75 years (interquartile range, 67-82), and the median CHA2DS2-VASc score was 4 (interquartile range, 3-5). A total of 5977 patients (62.5%) received care that was concordant with all guideline recommendations for which they were eligible. Rates of GC care were higher in patients treated by providers with greater specialization in arrhythmias (60.0%, 62.4%, and 67.0% for primary care physicians, cardiologists, and electrophysiologists, respectively; P<0.001). During a median of 30 months of follow-up, patients treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization. CONCLUSIONS: Over a third of patients with atrial fibrillation in this large outpatient registry received care that differed in some respect from guideline recommendations. There was no apparent association between GC care and improved risk-adjusted outcomes.
Authors: Jonathan G Tardos; Christopher J Ronk; Miraj Y Patel; Andrew Koren; Michael H Kim Journal: J Am Heart Assoc Date: 2021-03-09 Impact factor: 5.501
Authors: Shinwan Kany; Bruno Reissmann; Andreas Metzner; Paulus Kirchhof; Dawood Darbar; Renate B Schnabel Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787
Authors: Josep Maria Pepió Vilaubí; Domingo Orozco-Beltrán; Alessandra Queiroga Gonçalves; Dolors Rodriguez Cumplido; Carina Aguilar Martin; Adriana Lopez-Pineda; Vicente F Gil-Guillen; Jose A Quesada; Concepcion Carratala-Munuera Journal: Int J Environ Res Public Health Date: 2018-06-11 Impact factor: 3.390